Finzati - Logo
CGEN logo

Compugen Ltd.

CGENBiotechnology
$2.59
+0.03 (+1.37%)
Current price
EarningsLatest report: Jun 30, 2026
FAVORABLE PROFILEAttractiveConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Strong business quality with supportive growth and cash-flow evidence. Valuation still matters, but the historical ratio profile is favorable.
Market Cap
$225.04M
Growth
4.8%
Cash Flow
2/5
Trend
Volatile
Evidence
Stable or improving margins · 48.6%Positive revenue growth · 81.8%Positive free cash flow · 0.34Reasonable earnings multiple · 4.04Manageable debt level · 0.03
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$2.59
Change1.37%
Market Cap$225.04M
52W Range1.30 - 3.24
Beta2.78
Gross Margin87.29%
Oper. Margin43.05%
Profit Margin48.57%
Debt/Eq0.03
Current Ratio6.56
Quick Ratio6.56
Revenue 5Y4.81%

Investment DNA

How strong this company looks for long-term investors

74
out of 100
Business Quality
Margins, moat, returns
90/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
58/100
Price Attractiveness
Cheap or expensive today
93/100
Why this score
Stable or improving margins · 48.6%Positive revenue growth · 81.8%Positive free cash flow · 0.34Reasonable earnings multiple · 4.04Manageable debt level · 0.03Healthy liquidity · 6.56

Analyst view

Analyst sentiment and price target

Analyst sentiment
No vote count available
Bullish
0
Hold
0
Bearish
0
Price Target
2026-08-05
Low
$5.00
Mean
$5.00
Median
$5.00
High
$5.00

Company Overview

IPO: 8/11/2000
Industry: Biotechnology
P/B i: 1.39
Debt / Equity i: 0.03
Operating Margin: 43.05%
Net Margin: 48.57%
ROE i: -
ROIC: -

Financial Health

Score15 / 20
Debt / Equity: 0.03
Current Ratio: 6.56
Quick Ratio: 6.56
Status: Good

Insider Transactions

Recent executive and insider activity

Mahler Michelle
Transaction: 07/29/2026
BUY
Change
+18,000
Price
$2.26
Filing
07/30/2026
Type
BUY
Mahler Michelle
Transaction: 07/29/2026
BUY
Change
+13,500
Price
Not reported
Filing
07/30/2026
Type
BUY
ZWEIFACH SANFORD S
Transaction: 07/29/2026
BUY
Change
+10,000
Price
$2.26
Filing
07/30/2026
Type
BUY